Clinical trial of WashU Med nasal drop vaccine

A nasal drop vaccine against COVID-19 developed at WashU Med has entered clinical trials to evaluate its safety and effectiveness in preventing COVID-19 disease and transmission. The initial clinical trial — a phase 1 study focusing on the vaccine’s safety — is being conducted by Bharat Biotech, a biotechnology company based in India that licensed the technology. The vaccine’s early development was led by David Curiel, MD, PhD, the Distinguished Professor of Radiation Oncology, and Michael Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine.